#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Obliterative bronchiolitis Idiopathic inflammatory myopathy Palmoplantar pustulosis Breast angiosarcoma Cutaneous T-cell lymphoma stage I Gastric cancer Cushing's syndrome Becker's muscular dystrophy Neoplasm Anti-glomerular basement membrane disease Small cell lung cancer recurrent Endocrine ophthalmopathy Osteosarcoma metastatic Antisynthetase syndrome Brain abscess More trials…

    Learn about Rare Diseases

    Lymphangiosarcoma – Life with Disease Thrombotic thrombocytopenic purpura – Diagnostics Pituitary-dependent Cushing’s syndrome Leiomyosarcoma metastatic – Life with Disease Marfan’s syndrome – Trials in Disease Rhabdomyosarcoma – Treatment Mitochondrial myopathy – Diagnostics Primary biliary cholangitis Epidermolysis bullosa – Diagnostics Richter’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tulisokibart Alxn1850 Disitamab Vedotin Vidutolimod INOBRODIB Tamibarotene Juniper Berry Oil Navtemadlin Sodium Iodide (131I) Entecavir Sotagliflozin GSKVX000000070250 Epirubicin Imetelstat Sodium Sodium Phosphate Dodecahydrate Soya-Bean Oil Refined 7-Ethyl-10-Hydroxycamptothecin Oxcarbazepine Calcium Levofolinate Exemestane More therapies…

    Learn about Your Condition

    Atopic keratoconjunctivitis Dyspnoea Acquired ATTR amyloidosis Oral neoplasm Synovial sarcoma recurrent Viral myocarditis Constipation Essential hypertension Osteochondrodysplasia Arthralgia Torticollis Endotracheal intubation Cervix carcinoma recurrent Peritonitis Skin disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Antoine Lacassagne

Centre Antoine Lacassagne

33 Avenue De Valombrose, Nice, 06189, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • ANHYDROUS CALCIUM FOLINATE
    • Exl01
    • Fluorouracil Sodium
    France

  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Granisetron
    • Betamethasone Sodium Phosphate Ph. Eur
    • Aprepitant
    Belgium France Italy Poland Spain

  • Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Farletuzumab Ecteribulin
    • Lenvatinib
    France Spain

  • Study of E7386 and Lenvatinib for Patients with Liver, Colon, Endometrial, or Other Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    • Endometrial cancer
    • Hepatocellular carcinoma
    Investigated Drugs:
    • (6S,9As)-8-((6-(3-(4-Ethyl-1-Piperazinyl)-1-Azetidinyl)-2-Pyridinyl)Methyl)-6-((2-Fluoro-4-Hydroxyphenyl)Methyl)Hexahydro-4,7-Dioxo-N-(Phenylmethyl)-2-(2-Propen-1-Yl)-2H-Pyrazino(2,1-C)(1,2,4)Triazine-1(6H)-Carboxamide
    • Doxorubicin Hydrochloride
    • Lenvatinib
    Denmark France Italy Spain

  • Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

    Recruiting

    3 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • L-Isoleucyl-L-Isoleucyl-L-Seryl-L-Alanyl-L-Valyl-L-Valyl-Glycyl-L-Isoleucyl-L-Leucine
    • Sargramostim
    Austria Belgium France Germany Ireland Italy +4

  • Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Saruparib
    • Darolutamide
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Ipilimumab
    • Nivolumab
    Austria Belgium France Germany Italy Poland +1

  • Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Gozetotide
    • Apalutamide
    • Darolutamide
    Belgium France Ireland Italy The Netherlands Spain

  • Study on Tislelizumab for Cancer Patients with Molecular Residual Disease After Standard Treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride
    • Tislelizumab
    France

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Ipilimumab
    Austria Belgium Czechia Denmark Finland France +5
Previous Page
1 … 6 7 8 9 10 … 28
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!